Magnus Monetary Group LLC elevated its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 774.4% within the 2nd quarter, in response to its most up-to-date Kind 13F submitting with the Securities & Alternate Fee. The agency owned 105,221 shares of the corporate’s inventory after buying a further 93,187 shares in the course of the quarter. Johnson & Johnson contains about 1.7% of Magnus Monetary Group LLC’s portfolio, making the inventory its eleventh largest holding. Magnus Monetary Group LLC’s holdings in Johnson & Johnson had been value $15,379,000 as of its most up-to-date submitting with the Securities & Alternate Fee.
Quite a lot of different institutional buyers and hedge funds have additionally not too long ago purchased and bought shares of the inventory. Residents & Northern Corp grew its stake in shares of Johnson & Johnson by 3.5% within the 2nd quarter. Residents & Northern Corp now owns 1,884 shares of the corporate’s inventory valued at $275,000 after shopping for a further 63 shares within the final quarter. Carolinas Wealth Consulting LLC lifted its stake in Johnson & Johnson by 0.4% within the fourth quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the corporate’s inventory valued at $2,643,000 after buying a further 64 shares over the last quarter. Epic Belief Funding Advisors LLC grew its place in Johnson & Johnson by 3.6% within the second quarter. Epic Belief Funding Advisors LLC now owns 1,831 shares of the corporate’s inventory value $268,000 after buying a further 64 shares within the final quarter. Verity Asset Administration Inc. elevated its stake in shares of Johnson & Johnson by 2.0% in the course of the 4th quarter. Verity Asset Administration Inc. now owns 3,268 shares of the corporate’s inventory value $512,000 after buying a further 65 shares over the last quarter. Lastly, Clothing store Monetary LLC raised its holdings in shares of Johnson & Johnson by 0.4% in the course of the 2nd quarter. Clothing store Monetary LLC now owns 16,632 shares of the corporate’s inventory valued at $2,431,000 after buying a further 65 shares within the final quarter. Institutional buyers personal 69.55% of the corporate’s inventory.
Analysts Set New Worth Targets
A number of analysis corporations have commented on JNJ. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” ranking to a “impartial” ranking and lowered their goal value for the inventory from $160.00 to $150.00 in a analysis report on Tuesday, July twenty third. TD Cowen lowered their value goal on Johnson & Johnson from $195.00 to $185.00 and set a “purchase” ranking on the inventory in a report on Thursday, July 18th. Daiwa America lowered Johnson & Johnson from a “strong-buy” ranking to a “maintain” ranking in a report on Tuesday, July twenty third. StockNews.com upgraded Johnson & Johnson from a “purchase” ranking to a “strong-buy” ranking in a report on Friday, August sixteenth. Lastly, Cantor Fitzgerald restated an “obese” ranking and issued a $215.00 value goal on shares of Johnson & Johnson in a analysis word on Tuesday. Seven analysis analysts have rated the inventory with a maintain ranking, six have given a purchase ranking and one has issued a robust purchase ranking to the corporate’s inventory. Primarily based on knowledge from MarketBeat.com, the corporate presently has a mean ranking of “Reasonable Purchase” and a mean goal value of $173.21.
Learn Our Newest Inventory Evaluation on Johnson & Johnson
Insider Shopping for and Promoting
In different Johnson & Johnson information, VP Robert J. Decker bought 5,635 shares of the enterprise’s inventory in a transaction on Friday, August thirtieth. The shares had been bought at a mean value of $165.06, for a complete worth of $930,113.10. Following the sale, the vice chairman now owns 18,973 shares of the corporate’s inventory, valued at roughly $3,131,683.38. The sale was disclosed in a authorized submitting with the Securities & Alternate Fee, which is out there at this hyperlink. 0.16% of the inventory is owned by firm insiders.
Johnson & Johnson Worth Efficiency
Shares of Johnson & Johnson inventory opened at $167.27 on Thursday. The corporate has a debt-to-equity ratio of 0.44, a present ratio of 1.07 and a fast ratio of 0.85. The corporate has a market cap of $402.57 billion, a PE ratio of 10.43, a price-to-earnings-growth ratio of two.73 and a beta of 0.52. The agency has a fifty day transferring common value of $156.82 and a two-hundred day transferring common value of $153.70. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week excessive of $168.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final launched its earnings outcomes on Wednesday, July seventeenth. The corporate reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a web margin of 46.34% and a return on fairness of 36.60%. The enterprise had income of $22.45 billion in the course of the quarter, in comparison with analysts’ expectations of $22.33 billion. Throughout the identical quarter final 12 months, the corporate earned $2.80 earnings per share. The agency’s income was up 4.3% on a year-over-year foundation. Analysts anticipate that Johnson & Johnson will submit 10.02 EPS for the present 12 months.
Johnson & Johnson Declares Dividend
The corporate additionally not too long ago introduced a quarterly dividend, which might be paid on Tuesday, September tenth. Buyers of file on Tuesday, August twenty seventh might be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August twenty seventh. This represents a $4.96 dividend on an annualized foundation and a dividend yield of two.97%. Johnson & Johnson’s payout ratio is 30.92%.
Johnson & Johnson Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare discipline worldwide. The corporate’s Modern Medication section provides merchandise for numerous therapeutic areas, equivalent to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious illnesses comprising HIV/AIDS; neuroscience, consisting of temper problems, neurodegenerative problems, and schizophrenia; oncology, equivalent to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by means of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
Need to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Day by day – Enter your e-mail tackle under to obtain a concise day by day abstract of the most recent information and analysts’ scores for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE day by day e-mail publication.
